Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.61 |
| ▸ | AKT2 | P31751 | 18/20 | 0.61 |
| ▸ | AKT3 | Q9Y243 | 18/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30815799 | 0.92 | AKT1 (0.61) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL27227231 | 0.92 | AKT1 (0.61) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL27227078 | 0.91 | AKT1 (0.60) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL30815608 | 0.91 | AKT1 (0.60) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL30802276 | 0.91 | AKT1 (0.71) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL27226621 | 0.91 | AKT1 (0.71) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL30815655 | 0.89 | AKT1 (0.57) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL27227091 | 0.89 | AKT1 (0.57) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL30826574 | 0.88 | AKT1 (0.67) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL27263417 | 0.88 | AKT1 (0.67) | AKT1AKT2AKT3CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.